December 10, 2020
SymBio Pharmaceuticals LimitedFuminori Yoshida
Representative Director
President and Chief Executive Officer(Securities Code: 4582)

Commencement of in-house sales of the anti-cancer agent Treakisym®
TOKYO, Japan, December 10, 2020 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo,"SymBio") today announced that its license agreement for the co-development and commercializationof bendamustine hydrochloride in Japan with Eisai Co., Ltd. for the anticancer agent TREAKISYM®
expired on December 9, 2020, and that SymBio began sales through its own sales organization inJapan today.
Since its founding in March 2005, SymBio has aimed to evolve into a specialty pharmaceuticalcompany with a fully integrated sales operation. SymBio decided in October 2018 to transition to inhouse sales, as we believe that accurate communication of product information to healthcare
professionals will maximize business potential and value to shareholders. After two years ofpreparation, SymBio began operation of its nationwide sales system today.
A total of 62 medical representatives with extensive sales experience and highly specialized expertisein the hematology field have been assigned to major regions throughout the country. At the sametime, the Company established a Regulatory Affairs & Quality Assurance Division to furtherstrengthen the stable supply and quality assurance of products. In addition, SymBio has established anationwide distribution system in collaboration with the Suzuken Group and the Kyoso Mirai Group
as sole distributors, with two distribution centers, one in Eastern Japan and one in Western Japan,
and a partnership with S.D. Collabo Co., Ltd.
Statement from Fuminori Yoshida, President and CEO of SymBio: "We will achieve profitability as
the first step in our second inauguration by transitioning to a company with its own sales andmarketing force, and the moment has come to transform from an R&D-oriented venture to a fullfledged pharmaceutical company, maximizing the potential of our products."
SymBio does not expect the information presented herein to have any material impact on its financial
outlook for the fiscal year ending December 2020.

1

Contact
Investor Relations
Tel: +81 (0)3 5472 1125
About TREAKISYM®
TREAKISYM® (non-proprietary name: bendamustine hydrochloride), a cytocide anti-cancer drug firstused in Germany in the 1970s, is now widely used in more than 50 countries with indications for lowgrade non-Hodgkin’s lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia.
 TREAKISYM® Intravenous Infusion 100 mg was approved in October 2010 for manufacturing andmarketing for the indication of relapsed/refractory low-grade B-cell non-Hodgkin's lymphoma andmantle cell lymphoma in Japan.
 TREAKISYM® was approved for the additional indication of chronic lymphocytic leukemia in Japanin August 2016.
 TREAKISYM® was approved for the additional indications of first-line treatment of low-grade Bcell non-Hodgkin’s lymphoma and mantle cell lymphoma in Japan in December 2016.
 SymBio achieved the primary endpoint (overall response rate) in Phase III study of TREAKISYM®
in combination with rituximab as treatment for r/r DLBCL and submitted a partial change
application with respect to its marketing approval in May 2020.
 TREAKISYM® ready-to-dilute (“RTD”) liquid formulation was approved in Japan in September2020.
 SymBio aims to achieve annual sales of JPY 10 billion on a NHI drug price basis at the earliest
possible stage.
About SymBio Pharmaceuticals Limited
SymBio Pharmaceuticals Limited was established in March 2005 by Fuminori Yoshida who
previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen
Japan. In May 2016, SymBio incorporated its wholly-owned subsidiary in the U.S., SymBio Pharma
USA, Inc. (Headquarters: Menlo Park, California, President: Mr. Fuminori Yoshida). SymBio’s
underlying corporate mission is to “deliver hope to patients in need” as it aspires to be a leading
global specialty biopharmaceutical company dedicated to addressing underserved medical needs.

2